The Board of Directors of Roivant Sciences Ltd. has authorized a buyback plan on April 2, 2024.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
11.13 USD | +0.91% | +5.00% | -0.89% |
Apr. 05 | Arbutus Biopharma Obtains Favorable Court Order in Moderna Patent Lawsuit | MT |
Apr. 04 | Moderna Suffers Setback in Lawsuit by Arbutus | MT |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-0.89% | 8.97B | |
+26.47% | 664B | |
+26.74% | 567B | |
-6.33% | 354B | |
+19.35% | 330B | |
+4.23% | 286B | |
+13.43% | 234B | |
+4.71% | 199B | |
-9.53% | 196B | |
-4.04% | 148B |
- Stock Market
- Equities
- ROIV Stock
- News Roivant Sciences Ltd.
- Roivant Sciences Ltd. authorizes a Buyback Plan.